CYP2B6 and depressive disorder: However, the prevalence of 20.56% of poor phenotype for CYP2B6 reported in this study cannot be ignored because of its involvement in the metabolism of drugs commonly used for the treatment of cancer, HIV infection and depression, where the treatment is usually long term, and these drugs may be toxic due to poor metabolism.